South Korea’s biohealth exports are reaching record levels, but for healthtech startups, international expansion increasingly depends on something technology alone cannot provide: local regulatory knowledge, clinical relationships, reimbursement pathways and distribution.
South Korea’s biohealth industry is entering a new phase of international expansion. Biohealth exports reached a record $27.9 billion in 2025, up 10.3% from the previous year, according to the Ministry of Health and Welfare. The government has set a 2026 target of $30.4 billion and is expanding support for overseas regulatory response, consulting, marketing and local market establishment.
The momentum has continued. Biohealth exports reached $16.12 billion in the first half of 2026, up 17.5% year over year, with pharmaceutical exports alone reaching $6.06 billion. Yet exporting a healthcare product is not the same as building a healthcare business overseas.
For Korean healthtech startups, the difficult part often begins after the technology has been developed and regulatory approval is within reach. A product still needs to fit another country’s healthcare system, pricing structure, regulatory framework, clinical environment and distribution network.
That creates a different kind of globalization challenge: Korean companies may be able to export the technology, but they cannot necessarily export the market infrastructure around it.
Korea Has the Technology. The Market Access Problem Comes Next
Korea’s medical AI sector illustrates the opportunity. Lunit generated 95% of its first-half 2026 revenue overseas, reaching KRW 45.8 billion in total revenue, up 23% year over year. Overseas sales accounted for KRW 43.4 billion.
VUNO, meanwhile, is pursuing the US, Europe and Middle East, backed by a KRW 10 billion strategic investment specifically intended in part to support global expansion. Its HATIV P30 portable ECG device secured a sales agreement with Health Arena covering five Middle Eastern markets, including Egypt, the UAE, Saudi Arabia, Kuwait and Iraq. These examples point to an important distinction.
A Korean healthtech company can build a product that is technically ready for international markets. But that does not mean it has the relationships or knowledge needed to commercialize it. A medical AI system may require clinical validation with local hospitals. A digital health platform may need integration with existing hospital systems. A pharmaceutical distribution platform may need to navigate licensing, pricing and relationships between manufacturers, distributors and pharmacies. The product can be standardized. The healthcare ecosystem cannot.
What Can Travel, and What Has to Be Rebuilt
This distinction is central to how PulseTech, a Bangladesh-based pharmaceutical distribution technology company, is approaching international expansion.
Speaking with KoreaTechToday, Kazi Ashikur Rasul, Co-founder and CEO of PulseTech, said the underlying distribution problem is universal, while the infrastructure around that problem varies from country to country.
“The core need is universal: pharmaceutical companies everywhere need reliable distributors to get authentic medicines to pharmacies efficiently. That part of the model transfers directly. What’s also transferable is our technology-enabled distribution approach: the systems we use to manage ordering, inventory, and deliveries; the data discipline around demand forecasting and the way we layer on services like financing and pharmacy software. Those are built to be adapted, not reinvented, in each new market.”
The distinction becomes particularly relevant for Korean startups. Technology, software architecture and data practices can potentially travel across markets. But regulations, licensing, pricing, reimbursement and stakeholder relationships generally cannot.
Rasul added:
“What needs to be rebuilt locally is the market-specific layer: regulations and licensing, pricing dynamics, and relationships with key stakeholders- pharmaceutical companies, pharmacies, and regulators. That’s why we intend to enter international markets via partnerships with local distributors. The distribution need and our technology are the constants; our local partners help us handle everything specific to each market.”
That approach challenges the traditional assumption that international expansion means building an overseas operation largely from scratch.
Partnerships Are Becoming Commercial Infrastructure
For Korean healthtech companies, the right local partner can provide far more than distribution. It can shorten regulatory learning curves, open hospital relationships, provide clinical validation opportunities and help navigate reimbursement and procurement systems.
VUNO’s Middle East expansion provides a practical example. Rather than attempting to establish its own distribution network across multiple countries, the company signed a sales agreement with Health Arena covering five markets. Its broader global strategy also includes regulatory work and market development across the US and Europe.
Lunit’s international trajectory demonstrates another model. In 2025, 92% of its annual revenue came from overseas markets, and its global business has been supported by partnerships with major pharmaceutical and healthcare companies. By the first half of 2026, overseas revenue had risen to 95% of total sales. These strategies suggest that global scale in healthtech is increasingly built through networks, rather than simply through geographic expansion.
Asia’s Healthcare Markets Make Localization Harder
This is not exclusively a Korean problem. Asia contains some of the world’s fastest-growing healthcare markets, but they differ substantially in regulation, payment systems, clinical practices, healthcare infrastructure and distribution. That fragmentation can make international expansion expensive for startups. It also creates an opportunity for companies that can separate their technology from the market-specific layer. For a Korean startup, the question therefore should not simply be whether its product works outside Korea.
It should ask:
Which parts of the business create value everywhere, and which parts depend on local healthcare infrastructure?
That distinction can determine whether a company should build its own overseas operation, partner with a local distributor, work with hospitals, or collaborate with a global pharmaceutical or technology company.
The Next Stage of Korean Healthtech Globalization
Korea’s export numbers show that the country’s healthcare industry has established a significant international base. But the next stage will be harder. The challenge is moving from exporting products to embedding products into foreign healthcare systems. That requires local knowledge that cannot simply be downloaded or replicated from Korea.
Rasul believes the ability to adapt is ultimately what makes the model scalable.
“Because we deeply understand the pharmaceutical market and operate in a data-driven way, we can test and iterate our systems easily, as we expand.”
For Korean startups, that may be the more important lesson. Globalization does not necessarily require rebuilding everything for every country. Nor does it mean exporting the Korean operating model unchanged. The more scalable approach may be to standardize the technology while localizing the market interface.
Korean Healthtech Needs to Export Systems, Not Just Products
South Korea has demonstrated that it can produce pharmaceuticals, medical devices and medical AI capable of competing internationally. Record biohealth exports and the growing overseas revenues of companies such as Lunit show that global demand is already emerging.
But international healthcare markets reward more than technical quality. They reward companies that understand how regulation, reimbursement, clinical practice, procurement and distribution actually work on the ground.
That is why local partnerships should not necessarily be viewed as a temporary shortcut for Korean healthtech startups. They can become part of the globalization strategy itself. The companies most likely to scale across Asia may be those that know what not to standardize.
As Rasul puts it, “The distribution need and our technology are the constants; our local partners help us handle everything specific to each market.”
For Korean healthtech, the path from global technology to global adoption may therefore run not around local markets, but through them.
